Clinical Trial Update: Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating maintenance therapy with decitabine, venetoclax, and blinatumomab after hematopoietic stem cell transplantation in Philadelphi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Decitabine (Decitabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING